EUCTR2008-003327-23-CZ进行中（未招募）不适用
PHASE III, OPEN-LABEL, MULTICENTER INTERNATIONAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AN OCTREOTIDE IMPLANT VERSUS SANDOSTATIN LAR® DEPOT IN PATIENTS WITH ACROMEGALY
Endo Pharmaceuticals Solutions0 个研究点目标入组 140 人开始时间: 2008年8月7日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 140
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Male or female with acromegaly
- •2.Age = 18 years and = 80 years
- •3.Confirmed diagnosis of a growth hormone-secreting tumor based on historical data and meeting at least one of the following criteria (a or b):
- •a.Patients in whom an oral glucose tolerance test (OGTT) was performed and meeting all of the following (based on previous historical data):
- •i.GH = 1.0 ng/mL during the OGTT and
- •ii.IGF-1 level = 20% above the upper limit of age-and sex-adjusted normal value during the OGTT and
- •iii.Pituitary tumor demonstrable on MRI
- •b.Patients in whom an OGTT was not performed and meeting all of the following (based on previous historical data):
- •i.IGF-1 level = 20% above the upper limit of age-and sex-adjusted normal value and
- •ii.Confirmation of a growth hormone-secreting tumor on pathologic examination of tissue removed at surgery and
- •iii.Pituitary tumor demonstrable on MRI
- •4.No pituitary tumor present or has tumor present that is = 3 mm in distance from the optic chiasm
- •5.Received a stable dose of monthly octreotide depot injections for a minimum of 3 consecutive months immediately prior to Screening
- •6.Must show a response to octreotide treatment with documented laboratory results at the Screening visits (mean of Day -60 and Day -30 results) defined as follows:
- •a.IGF-1 < 20% above the upper limit of normal age and sex-adjusted levels and GH =5.0 ng/mL
- •7.Without, in the opinion of the investigator; clinically significant findings on physical exam, laboratory values, and vital signs; or unstable chronic medical conditions
- •8.Be able to communicate, complete questionnaires independently, provide and sign written informed consent, and willing to participate and comply with study requirements
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Women who are pregnant, lactating, or of child-bearing potential who are not practicing a medically acceptable method of birth control
- •2.Pituitary surgery less than 3 months prior to Screening
- •3.Liver disease (e.g., cirrhosis, chronic active or persistent hepatitis or persistent abnormalities of ALT, AST (level > 2X normal), alkaline phosphatase (level > 2X normal), or direct bilirubin (level > 1.5X normal))
- •4.Other laboratory values considered by the Investigator or Sponsor to be clinically significant
- •5.Unstable angina, sustained ventricular arrhythmias or heart failure (NYHA III and IV)
- •6.Acute myocardial infarction within 3 months of Screening
- •7.Uncontrolled diabetes defined as having a fasting glucose > 150 mg/dl and HbA1c = 9 %
- •8.Symptomatic cholelithiasis
- •9.History of drug or alcohol abuse within 6 months of Screening
- •10.Received any investigational drug or participated in another clinical trial within 30 days of Screening
- •11.Received radiotherapy for pituitary tumor or any radiotherapy above the neck at any time before the start of Screening
- •12.Received pegvisomant, lanreotide or a dopamine agonist within 3 months of Screening, or at any time during the trial
- •13.Received a previous octreotide implant
- •14.History or presence of significant cardiovascular, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, psychiatric disease, any other severe coexisting or terminal systemic disease that limits life expectancy or may interfere with the conduct of the study, or patients who are incarcerated in penal institutions or are committed to mental institutions
- •15.Candidate on a waiting list for surgery while on study
- •16.Patient who, through completion of the study, would have donated in excess of:
- •a.500 mL of blood in 42 days;
- •b.1500 mL of blood in 180 days; or
- •c.2500 mL of blood in 1 year
- •17. Received new or non-stable dose of hormone replacement therapy within 3 months of Screening
研究者
相似试验
进行中（未招募）
不适用
PHASE III, OPEN-LABEL, MULTICENTER INTERNATIONAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AN OCTREOTIDE IMPLANT VERSUS SANDOSTATIN LAR® DEPOT IN PATIENTS WITH ACROMEGALYMedDRA version: 9.1Level: LLTClassification code 10000599Term: AcromegalyAcromegalyEUCTR2008-003327-23-HUEndo Pharmaceuticals Solutions Inc140
进行中（未招募）
1 期
PHASE III, OPEN-LABEL, MULTICENTER INTERNATIONAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AN OCTREOTIDE IMPLANT VERSUS SANDOSTATIN LAR® DEPOT IN PATIENTS WITH ACROMEGALYAcromegalyEUCTR2008-003327-23-SKEndo Pharmaceuticals Solutions Inc140
进行中（未招募）
不适用
PHASE III, OPEN-LABEL, MULTICENTER INTERNATIONAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AN OCTREOTIDE IMPLANT VERSUS SANDOSTATIN LAR® DEPOT IN PATIENTS WITH ACROMEGALYMedDRA version: 9.1Level: LLTClassification code 10000599Term: AcromegalyAcromegalyEUCTR2008-003327-23-PLEndo Pharmaceuticals Solutions Inc.140
进行中（未招募）
不适用
Phase III, Open-Label, Multicenter International Study to Evaluate the Efficacy and Safety of an Octreotide Implant and/or Sandostatin LAR® depot in Patients with AcromegalyMedDRA version: 9.1Level: LLTClassification code 10000599Term: AcromegalyAcromegalyEUCTR2008-003327-23-DEEndo Pharmaceuticals Inc.140
进行中（未招募）
3 期
A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer (DESTINY-Breast 12)Breast CancerJPRN-jRCT2031210182Hanai Masaharu500